BR112023016672A2 - Composições compreendendo anticorpos humanizados contra ligante 1a semelhante a tnf (tl1a) e seus usos - Google Patents

Composições compreendendo anticorpos humanizados contra ligante 1a semelhante a tnf (tl1a) e seus usos

Info

Publication number
BR112023016672A2
BR112023016672A2 BR112023016672A BR112023016672A BR112023016672A2 BR 112023016672 A2 BR112023016672 A2 BR 112023016672A2 BR 112023016672 A BR112023016672 A BR 112023016672A BR 112023016672 A BR112023016672 A BR 112023016672A BR 112023016672 A2 BR112023016672 A2 BR 112023016672A2
Authority
BR
Brazil
Prior art keywords
tl1a
compositions
ligand
antibodies against
humanized antibodies
Prior art date
Application number
BR112023016672A
Other languages
English (en)
Inventor
Allison Luo
Bradley Henkle
Janine Bilsborough
Lauren Otsuki
Mark Manning
Olivier Laurent
Robert Payne
R Targan Stephan
Original Assignee
Cedars Sinai Medical Center
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Prometheus Biosciences Inc filed Critical Cedars Sinai Medical Center
Publication of BR112023016672A2 publication Critical patent/BR112023016672A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições compreendendo anticorpos humanizados contra ligante 1a semelhante a tnf (tl1a) e seus usos. são descritos, neste documento, anticorpos anti-tl1a humanizados e composições farmacêuticas para o tratamento da doença inflamatória intestinal (ibd), tal como doença de crohn (cd) e colite ulcerativa (uc).
BR112023016672A 2021-02-18 2022-02-17 Composições compreendendo anticorpos humanizados contra ligante 1a semelhante a tnf (tl1a) e seus usos BR112023016672A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US202163285781P 2021-12-03 2021-12-03
PCT/US2022/016841 WO2022178159A1 (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Publications (1)

Publication Number Publication Date
BR112023016672A2 true BR112023016672A2 (pt) 2023-11-21

Family

ID=82931032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016672A BR112023016672A2 (pt) 2021-02-18 2022-02-17 Composições compreendendo anticorpos humanizados contra ligante 1a semelhante a tnf (tl1a) e seus usos

Country Status (16)

Country Link
EP (1) EP4294444A1 (pt)
JP (1) JP2024506940A (pt)
KR (1) KR20230157973A (pt)
AU (1) AU2022223420A1 (pt)
BR (1) BR112023016672A2 (pt)
CA (1) CA3207817A1 (pt)
CL (1) CL2023002424A1 (pt)
CO (1) CO2023011969A2 (pt)
CR (1) CR20230436A (pt)
DO (1) DOP2023000162A (pt)
EC (1) ECSP23070237A (pt)
IL (1) IL305312A (pt)
MX (1) MX2023009622A (pt)
PE (1) PE20231681A1 (pt)
TW (1) TW202246322A (pt)
WO (1) WO2022178159A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
SG10201810298VA (en) * 2013-11-13 2018-12-28 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US20210070871A1 (en) * 2018-04-25 2021-03-11 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies

Also Published As

Publication number Publication date
JP2024506940A (ja) 2024-02-15
CL2023002424A1 (es) 2024-01-05
IL305312A (en) 2023-10-01
KR20230157973A (ko) 2023-11-17
CO2023011969A2 (es) 2023-09-29
ECSP23070237A (es) 2023-10-31
PE20231681A1 (es) 2023-10-19
EP4294444A1 (en) 2023-12-27
WO2022178159A1 (en) 2022-08-25
TW202246322A (zh) 2022-12-01
MX2023009622A (es) 2023-08-28
AU2022223420A1 (en) 2023-09-21
CR20230436A (es) 2023-11-01
CA3207817A1 (en) 2022-08-25
DOP2023000162A (es) 2023-10-15

Similar Documents

Publication Publication Date Title
CL2022001016A1 (es) Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
CO2022006679A2 (es) Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos
HRP20201600T1 (hr) Anti-pd-1 antitijelo i njegova uporaba
EA201892790A1 (ru) Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний
BR112023016445A2 (pt) Anticorpos anti-cd30l e seus usos
PH12021500012A1 (en) Inhibitors of keapi-nrf2 protein-protein interaction
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
MX2020008502A (es) Dosis para el tratamiento con proteinas de fusion il-22 fc.
BR112023016672A2 (pt) Composições compreendendo anticorpos humanizados contra ligante 1a semelhante a tnf (tl1a) e seus usos
Biswas et al. Hepatic Fibrosis and its Regression: The Pursuit of Treatment
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA202192330A1 (ru) Олигонуклеотиды, препятствующие экспрессии белка, ассоциированного с синдромом ломкой х-хромосомы, и способы их применения
EA201791686A1 (ru) Клизма для ректального введения
DOP2023000160A (es) Anticuerpos anti-cd30l y usos de estos
MX2020004706A (es) Composiciones orales de rifamicina sv.
RU2020127436A (ru) Композиция для лечения пациента, страдающего язвенным колитом, и применение композиции в качестве лекарственного средства
Durrheim Simply wearing footwear could interrupt transmission of Strongyloides stercoralis
PH12018500020A1 (en) Novel imide derivatives and use thereof as medicine
EA202190578A1 (ru) ИНГИБИТОРЫ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ KEAP1-Nrf2
WO2016199161A3 (en) A composition comprising pentosan polysulfate sodium for use in treatment of bladder outlet obstruction and/or lower urinary tract symptoms
Bajcetic¹ et al. INCIDENCE OF TUNNELED CUFFED VASCULAR CATHETERS INFECTION IN DIABETICS ON HEMODIALYSIS
BR112021006339A2 (pt) formulação de inibidor de imunoproteassoma
EA200900602A1 (ru) Применение альфа 1-тимозина для приготовления лекарства для профилактики и лечения аутоиммунных заболеваний
TR201711933A2 (tr) Ti̇rozi̇n ki̇naz 2 (tyk2) enzi̇mi̇ni̇ selekti̇f i̇nhi̇be eden heterosi̇kli̇k bi̇leşi̇kler